A patient enrolled in the phase 1 NADOM trial of darovasertib alone in non-metastatic uveal melanoma shows early signs of clinical efficacy.
Clinical Trials
Sequential Treatment With Immunotherapy and Targeted Therapy Denotes OS Benefit in BRAF-Mutant Melanoma
Immunotherapy in the form of ipilimumab (Yervoy) plus nivolumab (Opdivo) followed by the targeted therapy combination encorafenib (Braftovi) plus binimetinib (Mektovi) elicited an overall survival (OS) benefit in patients with untreated BRAF-mutated metastatic melanoma, according to findings from the phase 2 SECOMBIT trial (NCT02631447).
Naporafenib Combinations Prove Effective in NRAS-Mutant Unresectable/Metastatic Melanoma
The investigational type II RAF inhibitor naporafenib exhibited favorable efficacy with a tolerable safety profile in combination with rineterkib, trametinib (Mekinist), or ribociclib (Kisqali) in patients with previously treated, unresectable or metastatic melanoma, according to results from a phase 2 trial (NCT04417621) presented at the ESMO Congress 2022.
Addition of Neoadjuvant Pembrolizumab Improves EFS in Resectable Melanoma
Compared with adjuvant pembrolizumab (Keytruda) alone, the addition of neoadjuvant pembrolizumab significantly improved event-free survival (EFS) outcomes for patients with stage III-IV melanoma with a hazard ratio of 0.58 (95% CI, 0.39-0.87; P = .004), according to data from the phase 2 SWOG S1801 trial (NCT03698019).